U.S. Food and Drug Administration (FDA) has approved Bristol-Myers’s Opdivo injection, for treatment of urothelial carcinoma (mUC).
The bladder cancer is the fifth most diagnosed cancer, and urothelial carcinoma is the most common type of bladder cancer. Opdivo has already been approved for treating several types of cancer, including lung cancer, kidney cancer and advanced melanoma.
Bristol-Myers Squib in January posted fourth quarter net earnings of $1.1 billion, driven mostly by increased sales of Opdivo and Eliquis.
To remind, the New York headquartered company settled in January with Merck for infringing Opdivo patent to make a competitive drug Keytruda.